Clinical Trials Logo

Plasma Cell Neoplasm clinical trials

View clinical trials related to Plasma Cell Neoplasm.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05336383 Recruiting - Multiple Myeloma Clinical Trials

Phase II Study of Salvage Radiation Treatment After B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy for Relapsed Refractory Multiple Myeloma

Start date: May 31, 2022
Phase: Phase 2
Study type: Interventional

This study is a Phase II study to determine the preliminary safety and efficacy of salvage radiation treatment after BCMA CAR-T therapy in subjects with RRMM. The study population will consist of subjects with RRMM previously treated with SOC BCMA CAR-T cell therapy with active disease on the D30+ PET or other imaging scan after CAR-T infusion. Patients who are planned for salvage chemotherapy less than 14 days after completion of radiation treatment will be excluded. Radiation treatment will be to bony or soft tissue plasmacytomas in up to five radiation treatment fields to 10-20Gy (or equivalent dose in 2Gy fractions of 10-21Gy). Final dose, target, and technique are per treating radiation physician discretion within these guidelines. Thirty patients will be enrolled. The co-primary endpoints are objective response rate (ORR) at 6 months and duration of response (DOR) among responders.

NCT ID: NCT04354246 Recruiting - Lung Cancer Clinical Trials

COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies

Start date: March 31, 2020
Phase: Phase 1
Study type: Interventional

Phase 1 open label sequential dose escalation and cohort expansion study evaluating the safety, tolerability and preliminary antitumor activity of COM902 as monotherapy and in combination with COM701 in subjects with advanced malignancies.

NCT ID: NCT03999697 Recruiting - Clinical trials for Mantle Cell Lymphoma

A Clinical Research of CD22-Targeted CAR-T in B Cell Malignancies

Start date: December 1, 2018
Phase: Phase 1
Study type: Interventional

Evaluation of the efficacy and safety of CD22-targeted chimeric antigen receptor T(CAR-T) cells in the treatment of recurrent or refractory CD22 positive B cell acute lymphoblastic leukemia (B-ALL)